Summary of Study ST002192
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001389. The data can be accessed directly via it's Project DOI: 10.21228/M85T47 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002192 |
| Study Title | Amelioration of developmental programming of NAFLD in adult liver using PQQ |
| Study Type | Pre-natal and Post-natal Diet and PQQ treatment |
| Study Summary | Maternal obesity and consumption of a high-fat diet significantly elevate risk for pediatric non-alcoholic fatty liver disease (NAFLD), affecting 10% of children in the US. Almost half of these children are diagnosed with nonalcoholic steatohepatitis (NASH), a leading etiology for liver transplant. Animal models show that signs of liver injury and perturbed lipid metabolism asso-ciated with NAFLD begin in utero; however, safe dietary therapeutics to blunt developmental programming of NAFLD are unavailable. Using a mouse model of maternal Western-style diet (WD), we previously showed that pyrroloquinoline quinone (PQQ), a potent dietary antioxidant, protected offspring of WD-fed dams from development of NAFLD and NASH. Here, we used untargeted mass spectrometry-based lipidomics to delineate lipotoxic effects of WD on offspring liver and identify lipid targets of PQQ. PQQ exposure during pregnancy altered hepatic lipid profiles of WD-exposed offspring, upregulating peroxisome proliferator-activated receptor (PPAR) α signaling and mitochondrial fatty acid oxidation to markedly attenuate triglyceride accumulation beginning in utero. Surprisingly, the abundance of very long-chain ceramides, important in promoting gut barrier and hepatic function, was significantly elevated in PQQ-treated offspring. PQQ exposure reduced the hepatic phosphatidylcho-line/phosphatidylethanolamine (PC/PE) ratio in WD-fed offspring and improved glucose toler-ance. Notably, levels of protective n − 3 polyunsaturated fatty acids (PUFAs) were elevated in offspring exposed to PQQ, beginning in utero, and the increase in n − 3 PUFAs persisted into adulthood. Our findings suggest that PQQ supplementation during gestation and lactation augments pathways involved in the biosynthesis of long-chain fatty acids and plays a unique role in modifying specific bioactive lipid species critical for protection against NAFLD risk in later life. |
| Institute | University of Oklahoma Health Sciences Center |
| Department | Biochemistry and Molecular Biology, Harold Hamm Diabetes Center |
| Laboratory | Jonscher |
| Last Name | Jonscher |
| First Name | Karen |
| Address | 975 NE 10th Street BRC-N 362A, Oklahoma City, OK, 73104, USA |
| karen-jonscher@ouhsc.edu | |
| Phone | 3032294620 |
| Submit Date | 2022-04-20 |
| Num Groups | 4 |
| Total Subjects | 24 |
| Num Males | 24 |
| Publications | Jonscher, et al FASEB J 2017; Friedman, et al Hepatol Commun 2018 |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-04-20 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001389 |
| Project DOI: | doi: 10.21228/M85T47 |
| Project Title: | Protective effects of maternal PQQ on hepatic lipid metabolism throughout the lifespan |
| Project Type: | Diet study and fetal programming |
| Project Summary: | Maternal obesity and consumption of a high-fat diet significantly elevate risk for pediatric non-alcoholic fatty liver disease (NAFLD), affecting 10% of children in the US. Almost half of these children are diagnosed with nonalcoholic steatohepatitis (NASH), a leading etiology for liver transplant. Animal models show that signs of liver injury and perturbed lipid metabolism asso-ciated with NAFLD begin in utero; however, safe dietary therapeutics to blunt developmental programming of NAFLD are unavailable. Using a mouse model of maternal Western-style diet (WD), we previously showed that pyrroloquinoline quinone (PQQ), a potent dietary antioxidant, protected offspring of WD-fed dams from development of NAFLD and NASH. Here, we used untargeted mass spectrometry-based lipidomics to delineate lipotoxic effects of WD on offspring liver and identify lipid targets of PQQ. PQQ exposure during pregnancy altered hepatic lipid profiles of WD-exposed offspring, upregulating peroxisome proliferator-activated receptor (PPAR) α signaling and mitochondrial fatty acid oxidation to markedly attenuate triglyceride accumulation beginning in utero. Surprisingly, the abundance of very long-chain ceramides, important in promoting gut barrier and hepatic function, was significantly elevated in PQQ-treated offspring. PQQ exposure reduced the hepatic phosphatidylcho-line/phosphatidylethanolamine (PC/PE) ratio in WD-fed offspring and improved glucose toler-ance. Notably, levels of protective n − 3 polyunsaturated fatty acids (PUFAs) were elevated in offspring exposed to PQQ, beginning in utero, and the increase in n − 3 PUFAs persisted into adulthood. Our findings suggest that PQQ supplementation during gestation and lactation augments pathways involved in the biosynthesis of long-chain fatty acids and plays a unique role in modifying specific bioactive lipid species critical for protection against NAFLD risk in later life. |
| Institute: | University of Oklahoma Health Sciences Center |
| Department: | Biochemistry and Molecular Biology, Harold Hamm Diabetes Center |
| Laboratory: | Jonscher |
| Last Name: | Jonscher |
| First Name: | Karen |
| Address: | 975 NE 10th Street BRC-N 362A, Oklahoma City, OK, 73104, USA |
| Email: | karen-jonscher@ouhsc.edu |
| Phone: | 3032294620 |
| Funding Source: | NIDDK |
Subject:
| Subject ID: | SU002278 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Age Or Age Range: | 20-24 weeks |
| Gender: | Male |
| Animal Housing: | Vivarium University of Colorado Anschutz Medical Campus |
| Animal Light Cycle: | 12/12 |
| Animal Feed: | CH; 2019; Envigo, Indianapolis, IN or WD; TD.88137; Envigo |
| Animal Water: | Water or treated with 1.25 mg/L PQQ |
| Species Group: | Mammals |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Diet |
|---|---|---|
| SA210181 | 1990C | CTL |
| SA210182 | 5329A | CTL |
| SA210183 | 1991A | CTL |
| SA210184 | 1990B | CTL |
| SA210185 | 5329B | CTL |
| SA210186 | 5329C | CTL |
| SA210187 | 1991C | CTL |
| SA210188 | 1990A | CTL |
| SA210189 | 1996A | CTL |
| SA210190 | 1991B | CTL |
| SA210191 | 1996B | CTL |
| SA210192 | 1996C | CTL |
| SA210193 | 333A | CTL PQQ |
| SA210194 | 333B | CTL PQQ |
| SA210195 | 333C | CTL PQQ |
| SA210196 | 362B | CTL PQQ |
| SA210197 | 358C | CTL PQQ |
| SA210198 | 362C | CTL PQQ |
| SA210199 | 362A | CTL PQQ |
| SA210200 | 358A | CTL PQQ |
| SA210201 | 389B | CTL PQQ |
| SA210202 | 358B | CTL PQQ |
| SA210203 | 389A | CTL PQQ |
| SA210204 | 330A | CTL PQQ |
| SA210205 | 389C | CTL PQQ |
| SA210206 | 330B | CTL PQQ |
| SA210207 | 330C | CTL PQQ |
| SA210208 | 386A | WD |
| SA210209 | 386C | WD |
| SA210210 | 386B | WD |
| SA210211 | 361B | WD |
| SA210212 | 989B | WD |
| SA210213 | 372C | WD |
| SA210214 | 989A | WD |
| SA210215 | 989C | WD |
| SA210216 | 361C | WD |
| SA210217 | 361A | WD |
| SA210218 | 1007A | WD |
| SA210219 | 754C | WD |
| SA210220 | 754A | WD |
| SA210221 | 372B | WD |
| SA210222 | 1007B | WD |
| SA210223 | 754B | WD |
| SA210224 | 5328A | WD |
| SA210225 | 372A | WD |
| SA210226 | 5328C | WD |
| SA210227 | 1007C | WD |
| SA210228 | 5328B | WD |
| SA210229 | 703A | WD PQQ |
| SA210230 | 767B | WD PQQ |
| SA210231 | 767C | WD PQQ |
| SA210232 | 756B | WD PQQ |
| SA210233 | 767A | WD PQQ |
| SA210234 | 756C | WD PQQ |
| SA210235 | 756A | WD PQQ |
| SA210236 | 703C | WD PQQ |
| SA210237 | 703B | WD PQQ |
| SA210238 | 773C | WD PQQ |
| SA210239 | 773B | WD PQQ |
| SA210240 | 901C | WD PQQ |
| SA210241 | 768A | WD PQQ |
| SA210242 | 773A | WD PQQ |
| SA210243 | 901B | WD PQQ |
| SA210244 | 768B | WD PQQ |
| SA210245 | 901A | WD PQQ |
| SA210246 | 768C | WD PQQ |
| SA210247 | 727B | WD PQQ/WD |
| SA210248 | 739C | WD PQQ/WD |
| SA210249 | 727A | WD PQQ/WD |
| SA210250 | 766B | WD PQQ/WD |
| SA210251 | 739B | WD PQQ/WD |
| SA210252 | 766C | WD PQQ/WD |
| SA210253 | 766A | WD PQQ/WD |
| SA210254 | 727C | WD PQQ/WD |
| SA210255 | 181C | WD PQQ/WD |
| SA210256 | 179C | WD PQQ/WD |
| SA210257 | 179B | WD PQQ/WD |
| SA210258 | 179A | WD PQQ/WD |
| SA210259 | 181A | WD PQQ/WD |
| SA210260 | 181B | WD PQQ/WD |
| SA210261 | 743C | WD PQQ/WD |
| SA210262 | 743B | WD PQQ/WD |
| SA210263 | 743A | WD PQQ/WD |
| SA210264 | 739A | WD PQQ/WD |
| Showing results 1 to 84 of 84 |
Collection:
| Collection ID: | CO002271 |
| Collection Summary: | Livers were excised and snap frozen then 10-15 mg aliquots sent to the West Coast Metabolomics Center for analysis following standard protocols. |
| Sample Type: | Liver |
| Storage Conditions: | -80℃ |
| Collection Vials: | Cryotubes |
| Storage Vials: | Cryotubes |
Treatment:
| Treatment ID: | TR002290 |
| Treatment Summary: | Dams and offspring were fed either chow (CH) or western-style diet (WD), with or without PQQ in drinking water. A subset of WD-exposed offspring were weaned onto WD without PQQ. |
| Treatment: | WD and PQQ |
| Treatment Compound: | BioPQQ |
| Treatment Route: | Drinking water, ad libitem |
| Treatment Dose: | 1.25 mg/L |
| Treatment Doseduration: | 17-21 weeks |
| Treatment Vehicle: | drinking water |
Sample Preparation:
| Sampleprep ID: | SP002284 |
| Sampleprep Summary: | Tissue was homogenized and lipids extracted following standard protocols at the WCMC. Samples were prepared in triplicate |
| Sampleprep Protocol Filename: | OUHSC_SP_Extraction_Protocol_for_liver_multi-omic.pdf |
Chromatography:
| Chromatography ID: | CH002651 |
| Methods Filename: | SOP_Lipidomic_Analysis_by_UPLC_QTOF.pdf |
| Instrument Name: | Agilent 1200 |
| Column Name: | Waters Acquity CSH C18 (100 x 2.1mm,1.7um) |
| Chromatography Type: | Reversed phase |
Analysis:
| Analysis ID: | AN003587 |
| Analysis Type: | MS |
| Analysis Protocol File: | SOP_Lipidomic_Analysis_by_UPLC_QTOF.pdf |
| Chromatography ID: | CH002651 |
| Has Mz: | 1 |
| Has Rt: | 1 |
| Rt Units: | Minutes |
| Results File: | ST002192_AN003587_Results.txt |
| Units: | Peak area |
| Analysis ID: | AN003588 |
| Analysis Type: | MS |
| Analysis Protocol File: | SOP_Lipidomic_Analysis_by_UPLC_QTOF.pdf |
| Chromatography ID: | CH002651 |
| Has Mz: | 1 |
| Has Rt: | 1 |
| Rt Units: | Minutes |
| Results File: | ST002192_AN003588_Results.txt |
| Units: | Peak area |